Janne T. Backman (born in 1968) studied medicine at the University of Helsinki in Finland, and graduated in 1994. He completed his PhD in 1996, and specialist degree in clinical pharmacology in 2001. He is currently Professor in Clinical Pharmacology and Individual Medicine at Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital. Apart from teaching clinical pharmacology to medical students, Backman is responsible for directing the training program for medical specialists in clinical pharmacology and he is vice director of the Doctoral Program for Drug Research at his university. He is a member of the National Committee on Medical Research Ethics in Finland, board member of The Finnish Society of Clinical Pharmacology (FSCP), and the current treasurer of EACPT. Dr. Backman’s research interests have included drug–drug interactions, drug metabolism, pharmacogenetics, and other sources of individual variability in pharmacokinetics. Most recently, he has been particularly interested in mechanism-based inhibition of CYP enzymes, the role of metabolites as inhibitors of drug metabolism, CYP2C8-mediated drug-drug interactions, and interactions involving various kinase inhibitors. He has published about 150 original articles in international peer-reviewed journals, many of which have been cited frequently. In 2015, he was listed as Thomson Reuters Highly Cited Researcher in “Pharmacology and Toxicology”.

Shuang Lu is a second-year PhD student in Clinical Pharmacology at the School of Pharmaceutical Sciences, Fudan University, China. Her research centers on population pharmacokinetics (PPK) and pharmacokinetic–pharmacodynamic (PK/PD) modeling, with a particular passion for advancing scientific understanding in the medicinal cannabis field. She is actively involved in developing robust PopPK models, integrating real-world PK data, and exploring translational applications that support evidence-based clinical use of cannabinoids. Her work reflects a deep commitment to combining quantitative pharmacology with meaningful clinical impact.

Dr. Nan-Lin Wu is the Chief of Department of Dermatology at MacKay Memorial Hospital, Taipei, Taiwan, and a Professor at the Department of Medicine and Institute of Biomedical Sciences, MacKay Medical University, Taiwan. He earned his MD and PhD from National Taiwan University. Clinically, he specializes in psoriasis, atopic dermatitis, and other immunological skin diseases, having served as a principal investigator for numerous clinical trials in these fields. His research interests encompass inflammatory diseases, keratinocyte biology, natural/herbal compounds, photobiology, and clinical pharmacology.

Dominika is a PhD candidate at the Monash Institute of Pharmaceutical Sciences. Her PhD research focuses on the development of novel mechanisms-based mathematical models that can describe and predict full time-courses of bacterial growth and resistance emergence to combat multidrug-resistant bacteria that can cause life-threatening infections. She’s passionate about investigating ways to treat resistant bacterial “superbugs” by optimising dosing regimens of currently available antibiotics in the fight against antimicrobial resistance."

Amedeo De Nicolò, PhD, is an Associate Professor in Pharmacology at the University of Turin (UniTo) specializing in pharmacokinetics and PK/PD modeling. He holds a PhD in Medicine and Experimental Therapy, focusing his research on drug metabolism, particularly for HIV and infectious diseases, using advanced HPLC-MS/MS techniques.

Yanbiao Liu was previously trained in general and oncologic surgery in China and is now pursuing a PhD in pharmacology and biomedicine at Auckland University of Technology, New Zealand. His research focuses on the functional role of sperm-associated antigen 5 (SPAG5) in breast cancer and its influence on cellular responses to chemotherapeutic and targeted agents.